Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein

Damage to cells, tissue and other body parts in a mammalian host may be treated with a pharmaceutical composition produced using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The lymphokine or cytotoxin is preferably tumor necrosis factor and the biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a pharmaceutical composition may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.